Crohn's disease: Current treatment options

Archives of Disease in Childhood

Volumn 93, Issue 9, 2008, Pages 787-792

  Akobeng, Anthony K ^a  

^a BOOTH HALL CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OMEGA 3 FATTY ACID; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

CALORIC INTAKE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENTERIC FEEDING; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; LONG TERM CARE; LYMPHOMA; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; T CELL LYMPHOMA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NUTRITION THERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51449101025     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.128751     Document Type: Review

References (82)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA 1932;99:1323-9.
2. Aufses AH Jr. The history of Crohn's disease. Sur Clin North Am 2001;81:1-11.
3. Dalziel TK. Chronic interstitial enteritis. BMJ 1913;2:1068-70.
4. Shanahan F. Crohn's disease. Lancet 2002;359:62-9.
5. Hyams JS. Crohn's disease in children. Pediatr Clin North Am 1996;43:255-73.
6. Tysk C, Lyndberg E, Jamerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
7. Lashner BA, Brzezinski A. Clinical epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology 1994;10:374-83.
8. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish between 1968 and 1983: Marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut 1989;30:618-22.
9. Cosgrove NI, Al-Atia RF, Jenkins HR. The epidemiology of paediatric inflammatory bowel disease. Arch Dis Child 1996;74:460-1.
10. Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4.
11. Kessler BH, Levine JJ. Diagnosis of inflammatory bowel disease. In: Levine JJ, Pettei MJ, eds. Inflammatory bowel disease in children and adolescents. Switzerland: Harwood Academic, 1995.
12. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
13. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71.
14. Katz JA. Management of inflammatory bowel disease in adults. Dig Dis 2007;8:65-71.
15. Rufo PA, Bpousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302.
16. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6.
17. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate CD: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007;26:987-1003.
18. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2):11-7.
19. Summers RW, Switz DM, Session JT, et al. National Cooperative Crohn's disease study: result of drug treatment. Gastroenterology 1979;77:847-69.
20. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
21. Modigliani R, Mary J, Simon J, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990;98:811-8.
22. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72.
23. Bello CE, Garrett SD. Therapeutic issues in oral glucocorticoid use. Lippincotts Prim Care Pract 1999;3:333-41.
24. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res 2002;58(Suppl 1):33-8.
25. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Systeme Rev 2005; 4.
26. O'Moráin C, Segal AW, Levi AJ. Elemental diet as primary therapy of acute Crohn's disease: a controlled trial. BMJ 1984;288:1859-62.
27. Hunt JB, Payne -James JJ, Palmer KR, et al. A randomised controlled trial of elemental diet and prednisolone as primary therapy in acute exacerbations of Crohn's disease. Gastroenterology 1989;96:A224.
28. Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 1993;34:1198-202.
29. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:75-81.
30. Sanderson IR, Udeen S, Davies PS, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987;62:123-7.
31. Verma S, Brown S, Kirkwood B, et al. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000;95:735-9.
32. González-Huix F, de León R, Fernández- Bañares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993;34:778-82.
33. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.
34. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database System Rev 2007; 1.
35. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15.
36. Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000;31:3-5.
37. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.
38. Lochs H, Dejong C, Hammarqvist F, et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 2006;25:260-74.
39. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
40. Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980;303:1499-502.
41. van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980;21:632-5.
42. Schroder H, Evans DA. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 1972;13:278-84.
43. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83.
44. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92.
45. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's disease Study Group. Gastroenterology 1993;104:1293-301.
46. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88.
47. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
48. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
49. Papadikas KA, Targan SR. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterolgy 2000;119:1148-57.
50. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database System Revs 2003;4.
51. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
52. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
53. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.
54. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
55. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Systeme Rev 1998;3.
56. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database System Re 2004;4.
57. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006;12:1053-7.
58. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:427-30.
59. Andersson P, Olaison G, Bendtsen P, et al. Health related quality of life in Crohn's proctocolitis does not differ from a general population when in remission. Colorectal Dis 2003;5:56-62.
60. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database System Rev 2003;4.
61. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database System Rev 2001; 1.
62. Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-7.
63. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database System Rev 2007;(3).
64. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. Aliment Pharmacol Ther 2006;24:1333- 40.
65. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease?. Scand J Gastroenterol 2001;36:383-8.
66. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996;38:543-8.
67. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews 2005;(1).
68. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
69. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
70. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
71. Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment Pharmacol Ther 2008;27:11-8.
72. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
73. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006;23:451-63.
74. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
75. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
76. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for Maintenance Treatment of Crohn's disease: Results of the CLASSIC II Trial. Gut 2007;56:1232-9.
77. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
78. Pearson DC, May GR, Fick G, et al. Azathioprine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 1998;(4).
79. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
80. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9.
81. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2006;(4).
82. Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007;(2).